Drugs / OMEGA-3-PENTAENOIC ACIDS
OMEGA-3-PENTAENOIC ACIDS
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02310022 | Nov 2014 → May 2015 | hypertriglyceridemia | Matinas Biopharma, Inc | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04177680 | Jun → Nov 2020 | hypertriglyceridemia | Matinas BioPharma Nanotechnologies, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04662528 | Jun 2021 → Aug 2022 | — | Matinas Biopharma, Inc | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OMEGA-3-PENTAENOIC ACIDS | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650221 ↗ |
| Known as | MAT9001 | “OBJECTIVE: To evaluate MAT9001, an investigational prescription-only omega-3 fatty acid agent containing predominantly eicosapentaenoic acid (EPA) and docosapentaenoic acid, in...” PMID 28391875 ↗ Oct 2016 |
| Known as | omega-3 pentaenoic acid | “MAT9001 (omega-3 pentaenoic acid)” NCT04662528 ↗ |
| Modality | Small molecule | — CHEMBL4650221 ↗ |
| Route | Oral | “2g MAT9001 capsules twice daily with meals” NCT04177680 ↗ |